VIVES is a multi-sector fund that invests in projects with a positive societal impact
e-Peas stands for Electronic Portable Energy Autonomous Systems.
The company was founded in 2014 on the conviction that the trillions of connected IoT nodes that will be deployed in the next few...
GreenWatt, founded in Belgium in 2004 as a spin-off from the Catholic University of Louvain (UCLouvain), designs, develops and markets locally integrated "key-to-door" biogas plants for the food and...
Spinovit, a UCLouvain spin-off, is developing a method for the quantitative analysis of an oxygen-sensitive blood biomarker to measure endothelial dysfunction and prevent cardiovascular risks.
Cardio...
Philippe Mengal, past CEO Greenwatt:
"The support of VIVES was essential because it was first of all a demonstration of confidence at a very early stage of the company just out of UCL Laboratories...
Michel Detheux, CEO iTeos Therapeutics:
"VIVES has played a unique dual role as incubator and spin off investor during the inception of iTeos not only to shape the equity story, but also to connect...
Willem de Vos, Prof. at University of Wageningen; Patrice Cani, Prof. at UCLouvain; Jean-Christophe Malrieu, CEO A-Mansia:
"As founders and CEO of A-mansia BioTech we experienced essential support...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease